CARGO Therapeutics, Inc.

CARGO Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing curative cell therapies for cancer patients. Its programs, platform technologies, and manufacturing strategy are designed to directly address the chimeric antigen receptor (CAR) T-cell therapies. The CAR is a protein that has been engineered to modify T cells so they can recognize and destroy cancer cells. The Company’s lead program, firicabtagene autoleucel (CRG-022), is an autologous (derived from a patient’s cells) CD22 CAR T-cell product candidate. The Company is also engaged in evaluating CRG-022 in patients at earlier stages of disease, including large B-cell lymphoma (LBCL) and other hematologic malignancies. The Company is also leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic designed by the Company to enhance CAR T-cell persistence and trafficking to tumor lesions.